Skip to main content
. Author manuscript; available in PMC: 2018 Jan 6.
Published in final edited form as: Neuroscience. 2016 Nov 2;340:243–257. doi: 10.1016/j.neuroscience.2016.10.062

Figure 2. Delivery of AAV-Zif268 construct promotes overexpression of Zif268 in vitro and protects against GNX-induced mPFC Zif268 downregulation in vivo.

Figure 2

Map of the viral vector for AAV2.FLAG.EGR1 (Zif268) with the most relevant restriction sites and vector elements indicated and restriction enzyme digestion of uncut Zif268, cut with NotI, NotI + BglII, or XmaI (lanes 1, 2, 3, & 4, respectively) (A). Western blot analysis of HT22 cell lysates revealed that infection with AAV-Zif268 significantly increased amount of Zif268 as compared to the Control-treated cells (B). A diagram of representative medial prefrontal cortex (mPFC) injection placements based on the atlas of Paxinos and Watson (2007); additional rats’ injections were identified at similar points between the anterior-posterior levels shown here (C). Western blot analysis confirmed GNX-induced down-regulation of Zif268 in the mPFC of animals that received Control virus; Zif268 protein expression was unchanged in Sham and GNX animals that received bilateral injection of AAV-Zif268 (D). Data are presented as means ± SEM. *p<0.05 Control versus AAV-Zif268, **p<0.05 versus all groups, n=2 plates/group in vitro, n=3–4/group in vivo.